NCCN adds patient-friendly guideline for multiple myeloma

Back in September, the National Comprehensive Cancer Network (NCCN) published its first two clinical practice guidelines in oncology written for patients, one for breast cancer and the other for non-small cell lung cancer.

These are a tremendous breakthrough in cancer treatment; they make an otherwise opaque and complicated process much more transparent for the patient and caregiver, helping to clear some of the unnecessary mystique from cancer treatment.

Since those initial publications they have published another three patient-friendly practice guidelines, for ovarian cancer, prostate cancer and melanoma, and most recently they have published their sixth, this one covering the plasma cell cancer multiple myeloma.

You can find links for all the downloadable guidelines (in PDF) by clicking on this link.

By Ross Bonander

See also: The NCCN publishes first two patient-friendly clinical practice guidelines

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap